▲ +443.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ra Medical Systems in the last 3 months. The average price target is $31.50, with a high forecast of $50.00 and a low forecast of $7.00. The average price target represents a 443.10% upside from the last price of $5.80.
The current consensus among 3 investment analysts is to hold stock in Ra Medical Systems. This rating has held steady since January 2020, when it changed from a Buy consensus rating.
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.